PMID- 31403034
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231013
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 9
DP  - 2019
TI  - Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and 
      the Expression and Clinicopathological Correlations of Some Related Genes.
PG  - 683
LID - 10.3389/fonc.2019.00683 [doi]
LID - 683
AB  - Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV+ DLBCL) is a 
      rare type of lymphoma with a high incidence in elderly patients, poor drug 
      response, and unfavorable prognosis. Despite advances in genomic profiling and 
      precision medicine in DLBCL, EBV+ DLBCL remain poorly characterized and 
      understood. We include 236 DLBCL patients for EBV-encoded mRNA (EBER) in situ 
      hybridization detection and analyzed 9 EBV+ and 6 EBV negative cases by 
      next-generation sequencing (NGS). We then performed fluorescence in situ 
      hybridization (FISH) and immunohistochemistry (IHC) to analyze chromosome 
      rearrangements and gene expressions in 22 EBV+ and 30 EBV negative cases. The 
      EBER results showed a 9.3% (22/236) positive rate. The NGS results revealed 
      recurrent alterations in MYC and RHOA, components of apoptosis and NF-kappaB 
      pathways. The most frequently mutated genes in EBV+ DLBCL were MYC (3/9; 33.3%), 
      RHOA (3/9; 33.3%), PIM1 (2/9; 22.2%), MEF2B (2/9; 22.2%), MYD88 (2/9; 22.2%), and 
      CD79B (2/9; 22.2%) compared with KMT2D (4/6; 66.7%), CREBBP (3/6; 50.0%), PIM1 
      (2/6; 33.3%), TNFAIP3 (2/6; 33.3%), and BCL2 (2/6; 33.3%) in EBV-negative DLBCL. 
      MYC and KMT2D alterations stood out the most differently mutated genes between 
      the two groups. FISH detection displayed a lower rearrangement rate in EBV+ 
      cohort. Furthermore, KMT2D expression was highly expressed and associated with 
      poor survival in both cohorts. MYC was only overexpressed and related to an 
      inferior prognosis in the EBV+ DLBCL cohort. In summary, we depicted a distinct 
      mutation profile for EBV+ and EBV-negative DLBCL and validated the differential 
      expression of KMT2D and MYC with potential prognostic influence, thereby 
      providing new perspectives into the pathogenesis and precision medicine of DLBCL.
FAU - Zhou, Yangying
AU  - Zhou Y
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Xu, Zhijie
AU  - Xu Z
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Lin, Wei
AU  - Lin W
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Duan, Yumei
AU  - Duan Y
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Lu, Can
AU  - Lu C
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Su, Weiping
AU  - Su W
AD  - Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Yan, Yuanliang
AU  - Yan Y
AD  - Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Liu, Huan
AU  - Liu H
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Zhong, Meizuo
AU  - Zhong M
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Zhou, Jianhua
AU  - Zhou J
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Zhu, Hong
AU  - Zhu H
AD  - Department of Oncology, Xiangya Hospital, Central South University, Changsha, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20190725
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6669985
OTO - NOTNLM
OT  - EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL)
OT  - KMT2D
OT  - MYC
OT  - fluorescence in situ hybridizations
OT  - immunohistochemistry
OT  - next-generation sequencing
EDAT- 2019/08/14 06:00
MHDA- 2019/08/14 06:01
PMCR- 2019/01/01
CRDT- 2019/08/13 06:00
PHST- 2019/05/07 00:00 [received]
PHST- 2019/07/10 00:00 [accepted]
PHST- 2019/08/13 06:00 [entrez]
PHST- 2019/08/14 06:00 [pubmed]
PHST- 2019/08/14 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2019.00683 [doi]
PST - epublish
SO  - Front Oncol. 2019 Jul 25;9:683. doi: 10.3389/fonc.2019.00683. eCollection 2019.